Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DaxibotulinumtoxinA safety in glabellar lines
NCT03004248Phase 3Completed
- Sponsor
- Revance Therapeutics
- Start
- Dec 2016
- Primary completion
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of daxibotulinumtoxinA in glabellar lines, sponsored by Revance Therapeutics. Primary endpoint: Incidence of Treatment Emergent Adverse Events. Started Dec 2016; status: completed.
02
Drugs
daxibotulinumtoxinA
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT03004248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03004248.